---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004643"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T10:15:31.258901+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics begins trading on Nasdaq via direct listing under ticker FBLG

## Summary
- Direct listing commenced January 31, 2024 on the Nasdaq Global Market.
- Stock trades under ticker symbol FBLG.
- Company is a clinical-stage biotech focused on fibroblast-based therapies for chronic diseases.
- Registration statement on Form S-1 declared effective by SEC on January 24, 2024.
- No financial results or operational milestones were disclosed in the announcement.

## SEC filing metadata
- accession: 0001493152-24-004643
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224004643/0001493152-24-004643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224004643/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004643
- JSON: https://secwatch.observer/filing/0001493152-24-004643.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004643.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.